title: Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study.
abstract: OBJECTIVE
  To investigate a possible linkage between the use of fertility drugs for infertility and the risk of breast and ovarian cancers.
  
  
  METHODS
  Long-term, historic-prospective study.
  
  
  METHODS
  Fertility clinic in a university hospital.
  
  
  METHODS
  Files of 1,197 infertile women with a mean (+/- SD) follow-up of 17.9+/-5 years (21,407 person-years) were reviewed. Diagnoses, number of courses, and dosage of fertility drugs were extracted from the files.
  
  
  METHODS
  Cancers were identified by record linkage to the National Cancer Registry. Histopathologic reports and data on estrogen and progesterone receptors in breast cancer tissue were also reviewed.
  
  
  METHODS
  Standardized incidence ratio with 95% confidence interval (CI) were used for risk assessment.
  
  
  RESULTS
  Of 20 breast cancers (standardized incidence ratio, 1.40 [95% CI, 0.83-2.10]), 16 were detected among 780 women who had been exposed to 3,978 cycles of clomiphene citrate (CC) and/or hMG (standardized incidence ratio, 1.65 [95% CI, 0.94-2.68]). The standardized incidence ratio for this cancer was significantly increased only in patients with one or two CC treatments and a dose of < or =1,000 mg (2.6 [1.19-5.0] and 2.52 [1.21-4.64], respectively). Two cases of ovarian cancer (1 patient unexposed) were observed with no evidence of excessive risk. Six of the eight patients with data on estrogen and progesterone receptors were exposed to CC, and all tested positive for these receptors.
  
  
  CONCLUSIONS
  An association between the use of fertility drugs and an increased risk of breast and ovarian cancers has not been confirmed.
authors.affiliation: Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. gadp@bgumail.bgu.ac.il
authors.forename: G
authors.initials: G
authors.lastname: Potashnik
authors.forename: L
authors.initials: L
authors.lastname: Lerner-Geva
authors.forename: L
authors.initials: L
authors.lastname: Genkin
authors.forename: A
authors.initials: A
authors.lastname: Chetrit
authors.forename: E
authors.initials: E
authors.lastname: Lunenfeld
authors.forename: A
authors.initials: A
authors.lastname: Porath
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007247:Infertility, Female / Q000188:drug therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D011446:Prospective Studies; D012306:Risk; D013997:Time Factors
chemical_list: D005300:Fertility Agents, Female